THERALASE TECHNOLOGIES INC. chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/AC$ (N/A)
Beta 2.09
Market capitalization 61.28M
Operating cash flow -4.03M
ESG Scores unknown

Company description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. The company is developing TLD-1433, which is in Phase II for the treatment of non-muscle invasive bladder cancer. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of tissue healing, as well as TLC-1000 and TLC-2000 accessories. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiolog Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

Sector: Healthcare - Industry: Medical Devices

Financial data

Diluted earning per share

Net income vs Operating income

Asset vs Liabilities

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.29M 105.64k -714.91k 68.94k
Total Cashflows From Investing Activities -133.53k -533.21k -164.58k -100.82k
Net Borrowings -60.23k -60.23k -52.28k -56.62k
Total Cash From Financing Activities 2.13M 18.61M -57.56k -57.37k
Change To Operating Activities 19.94k -28.4k 51.9k -376.14k
Issuance Of Stock 1.55M 20.27M 175
Net Income -3.36M -7.41M -5.6M -4.41M
Change In Cash 779.8k 11.51M -4.67M -4.19M
Effect Of Exchange Rate
Total Cash From Operating Activities -1.22M -6.57M -4.45M -4.03M
Depreciation 222.93k 255.26k 272.28k 276.15k
Change To Account Receivables 238.94k -48.72k 343.06k 183.24k
Other Cashflows From Financing Activities 582.79k -1.6M -5.46k -750
Change To Netincome 186.89k 421.96k 929.74k 342.44k
Capital Expenditures -133.53k -533.21k -164.58k -100.82k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 1.7M 4.16M 3.45M 2.92M
Income Before Tax -3.36M -7.41M -5.6M -4.41M
Net Income -3.36M -7.41M -5.6M -4.41M
Selling General Administrative 2.61M 3.32M 2.52M 1.93M
Gross Profit 947.64k 338.65k 243.81k 278.88k
Ebit -3.37M -7.14M -5.72M -4.57M
Operating Income -3.37M -7.14M -5.72M -4.57M
Interest Expense -663 -12.36k -9.68k -5.34k
Income Tax Expense
Total Revenue 1.73M 964.05k 929.12k 780.64k
Cost Of Revenue 786.43k 625.4k 685.31k 501.76k
Total Other Income ExpenseNet 10.36k -271.69k 124.03k 161.55k
Net Income From Continuing Ops -3.36M -7.41M -5.6M -4.41M
Net Income Applicable To Common Shares -3.36M -7.41M -5.6M -4.41M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.57M 1.61M 857.13k 874.79k
Total Stockholder Equity 998.64k 13.86M 9.16M 5.07M
Other Current Liabilities 1.2M
Total Assets 3.56M 15.47M 10.02M 5.94M
Common Stock 26.43M 42.12M 42.12M 42.12M
Other Current Assets
Retained Earnings -35.24M -42.65M -48.51M -53.09M
Treasury Stock 3.81M 7.4M 5.3M 5.1M
Cash 1.03M 12.55M 7.88M 3.69M
Total Current Liabilities 2.57M 1.52M 821.41k 874.79k
Other Stockholder Equity 3.81M 7.4M 5.3M 5.1M
Property, Plant, and Equipment 672.69k 1.15M 1.04M 865.92k
Total Current Assets 2.74M 14.19M 8.92M 5M
Net Tangible Assets 980.64k 13.85M 9.16M 5.07M
Net Receivables 790.46k 824.13k 485.24k 300.04k
Accounts Payable 1.02M 525.2k 408.21k 496.41k


Insider Transactions

Here are the insider transactions of stock shares related to THERALASE TECHNOLOGIES INC.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Dumoulin-White (Roger John)Acquisition or disposition in the public market at price 0.25 per share.D2022-04-1810% Security Holder of Issuer32k
Dumoulin-White (Roger John)Acquisition or disposition in the public market at price 0.25 per share.D2022-04-0610% Security Holder of Issuer20k
Dumoulin-White (Roger John)Acquisition or disposition in the public market at price 0.23 per share.D2021-12-1610% Security Holder of Issuer33.3k
Dumoulin-White (Roger John)Acquisition or disposition in the public market at price 0.16 per share.D2021-10-0110% Security Holder of Issuer50k
Hachey (Kristina Maria)Acquisition or disposition in the public market at price 0.16 per share.D2021-09-22Senior Officer of Issuer50k
Dumoulin-White (Roger John)Acquisition or disposition in the public market at price 0.17 per share.D2021-09-1010% Security Holder of Issuer45k
Shirazi (Shawn)Acquisition or disposition in the public market at price 0.15 per share.D2021-08-20Senior Officer of Issuer5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to THERALASE TECHNOLOGIES INC.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on THERALASE TECHNOLOGIES INC.

Here is the result of two systematic investment strategies applied to THERALASE TECHNOLOGIES INC.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on THERALASE TECHNOLOGIES INC.

The following chart shows the equity curve of the two systematic investment strategies applied to THERALASE TECHNOLOGIES INC.:

THERALASE TECHNOLOGIES INC. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 4.24% on the backtest period.

Performance at glance

Performance

4.24 %

Latent gain

84.87 C$

Invested capital

2000.19 C$

Annualized return

1.02 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on THERALASE TECHNOLOGIES INC.

This is the result of two momentum investment strategies applied to THERALASE TECHNOLOGIES INC.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on THERALASE TECHNOLOGIES INC.

The following chart shows all the entries opened by the momentum investment system on THERALASE TECHNOLOGIES INC.:

THERALASE TECHNOLOGIES INC. momentum entries
  • The first momentum investment strategy would give 17.27% of return on THERALASE TECHNOLOGIES INC.. That represents 993.16C$ of latent gain with 5750.23C$ of employed capital.
  • The second momentum investment strategy would give 23.09% of return on THERALASE TECHNOLOGIES INC.. That represents 577.23C$ of latent gain with 2500.2C$ of employed capital.
Performance at glance (1Q Momentum)

Performance

17.27 %

Latent gain

993.16 C$

Invested capital

5750.23 C$

Annualized return

-7.03 %
Performance at glance (2Q Momentum)

Performance

23.09 %

Latent gain

577.23 C$

Invested capital

2500.2 C$

Annualized return

6.31 %

Momentum equity curve on THERALASE TECHNOLOGIES INC.

The following chart shows the equity curve of the two momentum strategies applied to THERALASE TECHNOLOGIES INC.:

THERALASE TECHNOLOGIES INC. momentum equity

Note: the dividends potentially given by THERALASE TECHNOLOGIES INC. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on THERALASE TECHNOLOGIES INC.

The following chart shows the employed capital evolution of the two momentum strategies on THERALASE TECHNOLOGIES INC. since the beginning:

THERALASE TECHNOLOGIES INC.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250C$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000C$.


Buy the dip strategy result on THERALASE TECHNOLOGIES INC.

Buy the dip entry openings on THERALASE TECHNOLOGIES INC.

THERALASE TECHNOLOGIES INC.

The performance achieved by the robo-advisor on THERALASE TECHNOLOGIES INC. is -15.04%. That represents -75.16$ of latent gain with 499.81C$ of employed capital. The following chart shows THERALASE TECHNOLOGIES INC. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of THERALASE TECHNOLOGIES INC., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-15.04 %

Latent gain

-75.16 C$

Invested capital

499.81 C$

Annualized return

-7.03 %

Equity curve of the strategy applied to THERALASE TECHNOLOGIES INC.

The following chart shows the result of the investment strategy applied to THERALASE TECHNOLOGIES INC.:

THERALASE TECHNOLOGIES INC.

Note: the dividends potentially given by THERALASE TECHNOLOGIES INC. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on THERALASE TECHNOLOGIES INC.

The following chart shows the employed capital evolution since the beginning of the investment strategy on THERALASE TECHNOLOGIES INC.:

THERALASE TECHNOLOGIES INC.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on THERALASE TECHNOLOGIES INC.

In this section, I will compare the three previous investment strategies applied to THERALASE TECHNOLOGIES INC..

Equity curve comparison on THERALASE TECHNOLOGIES INC.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

THERALASE TECHNOLOGIES INC. investment strategy comparison

Employed capital comparison on THERALASE TECHNOLOGIES INC.

THERALASE TECHNOLOGIES INC. investment comparison

Performance comparison on THERALASE TECHNOLOGIES INC.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 4.24% 84.87C$ 2000.19C$ 1.02%
Momentum 1 quarter 17.27% 993.16C$ 5750.23C$ 4.43%
Momentum 2 quarters 23.09% 577.23C$ 2500.2C$ 6.31%
Non-directional -15.04% -75.16C$ 499.81C$ -7.03%
Annualized return comparison

Automatic investment

1.02 %

Momentum 1Q

6.31 %

Momentum 2Q

6.31 %

Non-directional

-7.03 %

Correlated stocks

Here are the most positively and negatively correlated stocks with THERALASE TECHNOLOGIES INC.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between THERALASE TECHNOLOGIES INC. and the other stocks. There may be false positives or some missing correlated stocks. If the price of THERALASE TECHNOLOGIES INC. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name THERALASE TECHNOLOGIES INC.
Country Canada
City Toronto
Address 41 Hollinger Road
Phone 416 699 5273
Website www.theralase.com
FullTime employees
Industry Medical Devices
Sector Healthcare
Exchange XTSX
Ticker TLT.XTSX
Market www.tsx.com

THERALASE TECHNOLOGIES INC. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown